Cingulate Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value
Cingulate Inc. (CING) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value of $3.84 per share for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Notes
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue · last filed 2024-08-13
- Cingulate Inc. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for the quarter ending 2024-03-31 was $1.10, a 94.42% decline year-over-year.
- Cingulate Inc. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for the quarter ending 2023-03-31 was $19.70, a 900.00% increase year-over-year.
- Cingulate Inc. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for the quarter ending 2022-03-31 was $1.97.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2024-06-30 | $3.84 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $1.10 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $91.80 10-Q · filed 2024-08-13 | ||||
| 2023-09-30 | $0.71 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | $0.93 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $19.70 10-Q · filed 2024-05-08 | $0.99 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $1.00 10-Q · filed 2023-11-13 | ||||
| 2022-09-30 | $1.07 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $1.46 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | $1.97 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |